Prosensa to Present at the 66th Annual American Academy of Neurology (AAN) Annual Meeting and the 39th Annual Deutsche Bank H...
April 28 2014 - 8:00AM
Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical
company focusing on rare diseases with a high unmet medical need,
today announced that it will present at the following US
conferences:
▪66th American Academy of Neurology (AAN) Annual
Meeting, Philadelphia, PA
Poster presentation: Emerging Science
Session: 6:15pm EDT on Wednesday, April 30, 2014
Drisapersen treatment for Duchenne muscular dystrophy: results
of a 96-week follow-up of an open-label extension study following
two placebo-controlled trials
Presenter: Dr. Nathalie Goemans
The poster includes results up to Week 48 from the second
open-label extension study of drisapersen treatment in boys with
DMD (DEMAND IV/DMD114349), who had previously completed a 48-week,
double-blind, placebo-controlled treatment phase in one of two
Phase II feeder studies (DEMAND II/DMD114117 and DEMAND
III/DMD114044).
Breakfast Briefing (by invitation only): 7:30
-9:00am EDT on Thursday, May 1, 2014
Corporate Update: Hans Schikan, CEO & Giles
Campion, CMO
Poster Presentation: Dr. Nathalie Goemans
Q&A: Prosensa Management, Dr. Nathalie
Goemans (live) and Dr. Craig McDonald (by phone)
Dr. Goemans is a pediatrician, child neurologist and Head of the
Neuromuscular Reference Center for Children at the University
Hospitals Leuven (UHL). She is actively involved in the development
of protocols for international multicentre trials and is an
investigator in clinical trials in Duchenne Muscular Dystrophy
(DMD).
Dr. McDonald is a Professor and Chair of Physical Medicine and
Rehabilitation and a Professor of Pediatrics at the University of
California Davis School of Medicine. He is an internationally
recognized expert in the clinical management and rehabilitation of
neuromuscular diseases including muscular dystrophies and the
development of novel outcome measures for clinical
trials.
▪39th Annual Deutsche Bank Health Care Conference,
Boston, MA
Fireside Chat: 2:10pm EDT on Wednesday, May 7,
2014; Berndt Modig, CFO
Live webcasts of Prosensa's presentations at the AAN Breakfast
Briefing and the Deutsche Bank Health Care Conference will be
accessible through the Investors & Media section of the
corporate website at http://ir.prosensa.eu/events.cfm and will be
archived for 90 days.
Notes to editors
About Prosensa Holding N.V.
Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged
in the discovery and development of RNA-modulating therapeutics for
the treatment of genetic disorders. Its primary focus is on rare
neuromuscular and neurodegenerative disorders with a large unmet
medical need, including Duchenne muscular dystrophy (DMD), myotonic
dystrophy and Huntington's disease.
Prosensa's current portfolio includes six compounds for the
treatment of DMD, all of which have received orphan drug status in
the United States and the European Union. The compounds use an
innovative technique called exon-skipping to provide a personalized
medicine approach to treat different populations of DMD patients.
www.prosensa.com
CONTACT: Prosensa Holding N.V.
Celia Economides, Senior Director IR & Corporate Communications
Phone: +1 917 941 9059
Email: c.economides@prosensa.nl
Avidity Biosciences (NASDAQ:RNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avidity Biosciences (NASDAQ:RNA)
Historical Stock Chart
From Apr 2023 to Apr 2024